DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United Kingdom
  • /
  • Commercial Services
Published
09 Mar 25
Updated
31 Jul 26
Views
185
Not Invested
Rentokil InitialRTO
RTO logo
Fair Value
UK£5.01
Share price31 Jul
UK£3.3533.1% undervalued intrinsic discount
Loading
1Y-10.56%
7D-5.60%

RTO: Future Performance Will Balance Modest Revenue Tailwinds And Discount Rate Reductions

AN
AnalystConsensusTarget
AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
09 Mar 25
Updated
31 Jul 26
Views
185
Not Invested
Fair ValueUK£5.01
Share priceUK£3.35
33.1% undervalued intrinsic discount
Narrative
Updates18

Last Update 31 Jul 26

Fair value Decreased 5.34%

RTO: Dividend Progression And Margin Assumptions Will Support Stronger Future Upside

Analysts have slightly reduced their price target for Rentokil Initial to £5.01 from £5.29, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E multiples.

What’s in the News for Rentokil Initial

  • Rentokil Initial has recommended an interim dividend of 4.48 cents per share, described as up 8.0% year on year, under its progressive dividend policy. Source: Company key developments.
  • The interim dividend is first set in US dollars. The sterling amount is planned to be announced on 27 August 2026, based on the average closing spot exchange rates for the three working days starting 24 August 2026. Source: Company key developments.
  • Shareholders on the register at the close of business on 14 August 2026 are scheduled to be eligible for the interim dividend, with payment expected on 21 September 2026. Source: Company key developments.
  • The last day for dividend reinvestment plan elections for this interim dividend is indicated as 28 August 2026. Source: Company key developments.

Valuation Changes for Rentokil Initial

  • Fair Value has been reduced slightly to £5.01 from £5.29.
  • Discount Rate has risen slightly to 7.88% from 7.73%.
  • Revenue Growth assumption is now 4.72% from 4.30%.
  • Profit Margin assumption is now 9.79% from 9.06%.
  • Future P/E multiple has been reduced to 26.76x from 30.90x.
Read more
9 viewsusers have viewed this narrative update

Key Takeaways

  • Expansion of pest control and hygiene services, enhanced marketing, and improvements in customer retention are driving sustainable growth and recurring revenues.
  • Operational efficiencies, increased merger activity, and technology adoption position the company for higher margins and market share gains globally.
  • Delays in acquisition integration, rising liability costs, sluggish core business growth, and digital marketing challenges threaten profitability and hinder Rentokil Initial's revenue and margin improvements.

Catalysts

About Rentokil Initial
    Provides route-based services in North America, Europe, the United Kingdom, Asia, the Middle East, North Africa, Turkey, and Pacific.
What are the underlying business or industry changes driving this perspective?
  • Rentokil Initial is positioned to benefit from rising demand driven by global urbanization and increasing health & hygiene awareness, as evidenced by the continued expansion of its pest control and hygiene service businesses (organic and inorganic), suggesting room for above-GDP revenue growth over the long run.
  • Enhanced marketing and digital strategies (greater focus on organic lead generation, broader channel mix, rollout of satellite branches, and improved brand support) have begun reversing earlier lead flow challenges, laying the foundation for future growth in new customer contracts and higher recurring revenues.
  • Ongoing operational improvements, including predictive churn models and customer retention initiatives (e.g., Drive to 85%), target meaningful uplift in contract retention rates; even a modest increase (toward 82-85%) in North America could have a significant compounding effect on recurring revenues and future earnings.
  • Cost efficiency and scalability are set to improve through branch integrations and process optimization, with management reiterating a clear path to $100 million in cost savings and the potential for North American margins to move above 20% post-2026, directly supporting higher future net margins and earnings.
  • Continued ramp-up in M&A activity, technology-enabled service offerings, and focus on high-growth emerging markets (e.g., India, Indonesia) underpin Rentokil Initial's ability to capture market share as businesses increasingly outsource hygiene and pest control, enabling both top-line growth and long-term margin expansion.
Rentokil Initial Earnings and Revenue Growth

Rentokil Initial Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Rentokil Initial's revenue will grow by 4.7% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 4.5% today to 9.8% in 3 years time.
  • Analysts expect earnings to reach $802.1 million (and earnings per share of $0.27) by about July 2029, up from $322.0 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $704.7 million.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 26.8x on those 2029 earnings, down from 36.2x today. This future PE is greater than the current PE for the GB Commercial Services industry at 26.0x.
  • Analysts expect the number of shares outstanding to grow by 0.16% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.88%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • North American contract portfolio revenues declined slightly year-on-year (down 0.2% ex-acquisitions), illustrating continued underperformance in the core recurring business; if execution risks or competitive pressures persist, revenue growth and margin improvements may remain subdued.
  • Integration of recent acquisitions (especially Terminix) is behind original timelines, with not all branches expected to be fully integrated by the end of 2026-raising risks to synergy realization and the $100 million cost-savings plan, which could weigh on net margins and post-integration earnings.
  • The cost per termite warranty claim rose by 9% in the period, and the provision for termite damages increased by $40 million to $276 million, signaling ongoing liability volatility and elevated claims costs that could pressure future profitability and increase earnings unpredictability.
  • Growth in Hygiene & Wellbeing is sluggish (only 0.4% organic growth in Q2) with headwinds including non-repeat COVID-driven contracts, softness in the U.K. commercial property market, and lumpiness in sectors like cruise shipping-with knock-on risks to segment revenue and group diversification benefits.
  • Rapid digital and search landscape changes (e.g., Google AI search summaries reducing direct website leads) pose challenges to digital marketing effectiveness, potentially increasing customer acquisition costs or reducing inbound lead generation, which could limit contract sales growth and affect both near
  • and long-term revenues.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of £5.01 for Rentokil Initial based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of £6.3, and the most bearish reporting a price target of just £4.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $8.2 billion, earnings will come to $802.1 million, and it would be trading on a PE ratio of 26.8x, assuming you use a discount rate of 7.9%.
  • Given the current share price of £3.45, the analyst price target of £5.01 is 31.2% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Rentokil Initial?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Comments

0 comments

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

RTO logo
Rentokil Initial
14.7% undervalued intrinsic discount

Rising Costs And Risks Will Hamper Pest Control Prospects

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 3 Sep
Read Narrative
RTO logo
Rentokil Initial
43.5% undervalued intrinsic discount

Digital Integration And Urbanization Will Expand Market Opportunities

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 14 Aug
Read Narrative

Fair Value vs Share Price

UK£5.01
vs UK£3.3533.1% undervalued intrinsic discount
PastFuture-123m8b2015201820212024202620272029Revenue US$8.2bEarnings US$802.1m
4.7%
Revenue growth
9.8%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Rentokil Initial

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Reasonable growth potential and fair value.

Market capUK£8.4b
PB2.1x
Estimated Growth4.2%
Dividend Yield2.7%
Full analysis

CEO & management

Michael Duffy
CEO
7.4yrs
CEO Tenure

Provides route-based services in North America, Europe, the United Kingdom, Asia, the Middle East, North Africa, Turkey, and Pacific.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide